新生血管性年龄相关性黄斑变性患者房水中HTRA1与TGF-β1的浓度
本研究采用ELISA法检测23例继发于AMD的初治脉络膜新生血管患者接受连续三个月每月0.5 mg雷珠单抗玻璃体腔注射前后房水中HTRA1、TGF-β1、BMP4、GDF6及VEGFA浓度,并以23例年龄匹配的白内障患者为对照。结果显示初治患者基线HTRA1、TGF-β1、VEGFA均高于对照,治疗后TGF-β1持续升高而HTRA1恢复至对照水平。
要点
- 初治nCNV患者基线房水HTRA1、TGF-β1、VEGFA均高于年龄匹配白内障对照。
- 雷珠单抗治疗后HTRA1恢复至对照水平,而TGF-β1持续升高。
- BMP4与GDF6在所有样本中均未检出。
核心结论
- 在nCNV患者中,HTRA1与TGF-β1显著高于对照。
- 治疗后TGF-β1持续升高,而HTRA1恢复至对照水平,提示TGF-β1与HTRA1参与新生血管性AMD,且TGF-β1具有不依赖VEGFA的作用。
研究设计与样本
- 研究纳入23例继发于AMD的初治脉络膜新生血管患者,接受连续三个月每月0.5 mg雷珠单抗玻璃体腔注射。
- 在基线(第一次注射前)、第1个月(第二次注射前)和第2个月(第三次注射前)采集房水,采用ELISA法检测HTRA1、TGF-β1、BMP4、GDF6和VEGFA浓度。
- 以23例年龄匹配的白内障患者作为对照。
主要发现
- BMP4与GDF6在所有样本中均未检出。
- 基线HTRA1高于对照(P < 0.0001),并高于第1个月(P < 0.0001)和第2个月(P < 0.0001)值。
- 基线VEGFA高于对照(P < 0.0001),与第1个月值无差异(P = 0.0821),但高于第2个月值(P < 0.0001)。
- 基线TGF-β1高于对照(P = 0.0015),与第1个月(P = 0.129)和第2个月(P = 0.5529)值无差异。
- 初治患者中HTRA1与TGF-β1、HTRA1与VEGFA、TGF-β1与VEGFA浓度之间均未发现相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate the expression of high-temperature requirement A serine peptidase 1 (HTRA1), TGF-β1, bone morphogenetic protein 4 (BMP4), growth differentiation factor 6 (GDF6), and VEGFA proteins in the aqueous humor of patients with naïve choroidal neovascularization (nCNV) secondary to AMD. METHODS: We measured by ELISA the concentrations of HTRA1, TGF-β1, BMP4, GDF6, and VEGFA in the aqueous humor of 23 patients affected by nCNV who received three consecutive monthly intravitreal injections of 0.5 mg ranibizumab. Samples were collected at baseline (before the first injection), month 1 (before the second injection), and month 2 (before the third injection). Twenty-three age-matched cataract patients served as controls. RESULTS: Bone morphogenetic protein 4 and GDF6 were not detectable in any samples. Baseline HTRA1 was higher than controls (P < 0.0001) and higher than both the month 1 (P < 0.0001) and the month 2 (P < 0.0001) values. Baseline VEGFA was higher than controls (P < 0.0001), not different from month 1 value (P = 0.0821), but higher than month 2 value (P < 0.0001). Baseline TGF-β1 was higher than controls (P = 0.0015) and not different from month 1 (P = 0.129) and month 2 values (P = 0.5529). No correlation was found in naïve patients between concentrations of HTRA1 and TGF-β1, HTRA 1 and VEGFA, or TGF-β1 and VEGFA. CONCLUSIONS: In nCNV patients, HTRA1 and TGF-β1 were significantly higher compared to controls. After treatment, TGF-β1 was persistently elevated, while HTRA1 returned to control levels, suggesting the involvement of TGF-β1 and HTRA1 in neovascular AMD and a VEGFA-independent role for TGF-β1.
引用
- Tosi GM, Caldi E, Neri G, et al. HTRA1 and TGF-β1 Concentrations in the Aqueous Humor of Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017. PMID: 28114575. doi:10.1167/iovs.16-20922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。